All In Biotech

Drug Trial Radar · NCT06257264

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

103

Actual

Start

Mar 11, 2024

Primary completion

Aug 27, 2026

Study completion Aug 27, 2027

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501 in participants with advanced, nonresectable, or metastatic solid tumors as monotherapy and in combination with fulvestrant with or without BGB-43395, a selective CDK4 inhibitor, in adults with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (BC). The study will also identify a recommended dose for expansion (RDFE) for BG-68501 as monotherapy and in combination for subsequent disease directed studies. The study will be conducted in 2 parts: Part 1 (dose escalation and safety expansion, including evaluation of food effect) and Part 2 (dose expansion).

Conditions

  • Breast Cancer
  • Small Cell Lung Cancer
  • Ovarian Cancer
  • Gastric Cancer
  • Hormone-receptor-positive Breast Cancer
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Advanced Solid Tumor
  • Endometrial Cancer
  • Prostate Cancer
  • TNBC - Triple-Negative Breast Cancer
  • GastroEsophageal Cancer
  • Bladder Cancer

Interventions

  • BG-68501Drug

    Planned doses administered orally.

  • FulvestrantDrug

    Standard dose administered via intramuscular injection.

  • BGB-43395Drug

    Planned doses administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; approximately 6-12 months
  2. Part 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BG-68501Time frame: Up to approximately 24 months
  3. Part 1: Recommended dose(s) for Expansion (RDFE) of BG-68501 monotherapy in participants with solid tumorsTime frame: Up to approximately 24 months
  4. Part 1: RDFE of BG-68501 in combination with fulvestrant and BGB-43395 in participants with HR+/HER2- BCTime frame: Up to approximately 24 months
  5. Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 20 months

Locations

24 sites in 6 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Presbyterian

    Newport Beach, California

  • Florida Cancer Specialists and Research Institute

    Lake Mary, Florida

  • Washington University School of Medicine

    St Louis, Missouri

  • Titan Health Partners Llc Dba Astera Cancer Care

    East Brunswick, New Jersey

  • Avera Cancer Institute

    Sioux Falls, South Dakota

  • Mary Crowley Cancer Research

    Dallas, Texas

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • Saint Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Nepean Hospital

    Kingswood, New South Wales, Australia

  • Genesiscare North Shore

    St Leonards, New South Wales, Australia

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Cancer Research South Australia

    Adelaide, South Australia, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)

    Guangzhou, Guangdong, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Shengjing Hospital of China Medical Universityhuaxiang Branch

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Xian Jiaotong University

    Xi'an, Shaanxi, China

  • Rambam Health Care Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • The Institute of Oncology, Arensia Exploratory Medicine

    Chisinau, Moldova

  • Auckland City Hospital

    Auckland, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.